Esophageal cancer carries an immense burden of disease. Despite advances in cancer care, the survival rate of esophageal cancer has not significantly improved over the last 30 years. The burden of disease is greater on minorities, immigrants, and lower socioeconomic groups in the United States. Research has consistently shown that these communities suffer from persistently worse outcomes. Minorities are noted to have increased risk of developing esophageal cancer, have worse stage at presentation, and limited access to the newest advancements and best treatment options. The reason for these disparities is multifactorial and the US health system must address and correct the underlying reasons to ensure just health care for all.
AjaniJAD'AmicoTABentremDJ, et al. Esophageal and esophagogastric junction cancers, version 2.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2019;17(7):855-883. doi:10.6004/jnccn.2019.0033
2.
Domper ArnalMJFerrández ArenasLanas Arbeloa. Esophageal cancer: risk factors, screening and endoscopic treatment in Western and Eastern countries. World J Gastroenterol. 2015;21(26):7933-7943. doi:10.3748/wjg.v21.i26.7933
3.
El-SeragHBMasonACPetersenNKeyCR. Epidemiological differences between adenocarcinoma of the oesophagus and adenocarcinoma of the gastric cardia in the USA. Gut. 2002;50(3):368-372. doi:10.1136/gut.50.3.368
4.
TorreLASiegelRLWardEMJemalA. Global cancer incidence and mortality rates and Trends–An update. Cancer Epidemiol Biomark Prev. 2016;25:16-27.
5.
SiegelRLMillerKDWagleNSJemalA. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17-48. doi:10.3322/caac.21763
6.
SarvepalliSGargSKSarvepalliSS, et al. Inpatient burden of esophageal cancer and analysis of factors affecting in-hospital mortality and length of stay. Dis Esophagus. 2018;31(9):doy022. doi:10.1093/dote/doy022
7.
NahvijouAArabMFaramarziAHashemiSYJavan-NoughabiJ. Burden of esophageal cancer according to World Health Organization regions: review of findings from the Global Burden of Disease Study 2015. Health Scope. 2019;8(3):e64984. doi:10.5812/jhealthscope.64984
8.
CaiYLinJWeiWChenPYaoK. Burden of esophageal cancer and its attributable risk factors in 204 countries and territories from 1990 to 2019. Public Health Front. 2022;10:952087. doi:10.3389/fpubh.2022.952087
9.
DelmanAMAmmannAMTurnerKMVaysburgDMVan HarenRM. A narrative review of socioeconomic disparities in the treatment of esophageal cancer. J Thorac Dis. 2021;13(6):3801-3808. doi:10.21037/jtd-20-3095
10.
OkerekeICWestraJTylerD, et al. Disparities in esophageal cancer care based on race: a National Cancer Database analysis. Dis Esophagus. 2022;35:(6):doab083. doi:10.1093/dote/doab083
11.
PetersenRPanLBlanckHM. Racial and ethnic disparities in adult obesity in the United States: CDC's tracking to inform state and local action. Prev Chronic Dis. 2019;16:E46. doi:10.5888/pcd16.180579
OgdenCLFryarCDMartinCB, et al. Trends in obesity prevalence by race and Hispanic origin-1999-2000 to 2017-2018. JAMA. 2020;324(12):1208-1210. doi:10.1001/jama.2020.14590
14.
KruegerPMReitherEN. Mind the gap: race/ethnic and socioeconomic disparities in obesity. Curr Diabetes Rep. 2015;15(11):95. doi:10.1007/s11892-015-0666-6
15.
RubensteinJHTaylorJB. Meta-analysis: the association of oesophageal adenocarcinoma with symptoms of gastro-oesophageal reflux. Aliment Pharmacol Ther. 2010;32(10):1222-1227. doi:10.1111/j.1365-2036.2010.04471.x
16.
YeWChowWHLagergrenJYinLNyrénO. Risk of adenocarcinomas of the esophagus and gastric cardia in patients with gastroesophageal reflux diseases and after antireflux surgery. Gastroenterology. 2001;121(6):1286-1293. doi:10.1053/gast.2001.29569
17.
LagergrenJYeWLagergrenPLuY. The risk of esophageal adenocarcinoma after antireflux surgery. Gastroenterology. 2010;138(4):1297-1301. doi:10.1053/j.gastro.2010.01.004
18.
El-SeragHBPetersenNJCarterJ, et al. Gastroesophageal reflux among different racial groups in the United States. Gastroenterology. 2004;126(7):1692-1699. doi:10.1053/j.gastro.2004.03.077
19.
FriedenbergFKRaiJVanarV, et al. Prevalence and risk factors for gastroesophageal reflux disease in an impoverished minority population. Obes Res Clin Pract. 2010;4(4):e261-e269. doi:10.1016/j.orcp.2010.06.001
20.
ShorttNKTischCPearceJ, et al. A cross-sectional analysis of the relationship between tobacco and alcohol outlet density and neighbourhood deprivation. BMC Public Health. 2015;15:1014. doi:10.1186/s12889-015-2321-1
21.
SongQWangXYuITS, et al. Processed food consumption and risk of esophageal squamous cell carcinoma: A case-control study in a high risk area. Cancer Sci. 2012;103(11):2007-2011. doi:10.1111/j.1349-7006.2012.02387.x
22.
WheelerJBReedCE. Epidemiology of esophageal cancer. Surg Clin N Am. 2012;92(5):1077-1087. doi:10.1016/j.suc.2012.07.008
23.
AllcottHDiamondRDubéJ-PHandburyJRahkovskyISchnellM. Food deserts and the causes of nutritional inequality. Q J Econ. 2019;134(4):1793-1844. doi:10.1093/qje/qjz015
24.
ShortMWBurgersKGFryVT. Esophageal cancer. Am Fam Physician. 2017;95(1):22-28.
25.
AsokanSSridharPQureshiMM, et al. Presentation, treatment, and outcomes of vulnerable populations with esophageal cancer treated at a Safety-Net Hospital. Semin Thorac Cardiovasc Surg. 2020;32(2):347-354. doi:10.1053/j.semtcvs.2019.12.008
26.
Highlights of the 2017 U.S. PIAAC Results Web Report (NCES 2020-777). U.S. Department of Education. Institute of Education Sciences, National Center for Education Statistics. https://nces.ed.gov/surveys/piaac/current_results.asp
27.
ArnettMJThorpeRJJr.GaskinDJBowieJVLaVeistTA. Race, medical mistrust, and segregation in primary care as usual source of care: findings from the exploring health disparities in integrated communities study. J Urban Health Bull New Y Acad Med. 2016;93(3):456-467. doi:10.1007/s11524-016-0054-9
28.
GaskinDJDinwiddieGYChanKSMcClearyRR. Residential segregation and the availability of primary care physicians. Health Serv Res. 2012;47(6):2353-2376. doi:10.1111/j.1475-6773.2012.01417.x
29.
LandonBEOnnelaJPMeneadesLO'MalleyAJKeatingNL. Assessment of racial disparities in primary care physician specialty referrals. JAMA Netw Open. 2021;4(1):e2029238. doi:10.1001/jamanetworkopen.2020.29238
30.
KatzmanJGChristianoAS. Clinicians as trusted messengers - the “secret sauce” for vaccine confidence. JAMA Netw Open. 2022;5(12):e2246634. doi:10.1001/jamanetworkopen.2022.46634
31.
StitzenbergKBSigurdsonEREglestonBLStarkeyRBMeropolNJ. Centralization of cancer surgery: implications for patient access to optimal care. J Clin Oncol. 2009;27(28):4671-4678. doi:10.1200/jco.2008.20.1715
32.
WolfeMKMcDonaldNCHolmesGM. Transportation barriers to health care in the United States: Findings from the National Health Interview Survey, 1997-2017. Am J Public Health. 2020;110(6):815-822. doi:10.2105/ajph.2020.305579
33.
NapierKJScheererMMisraS. Esophageal cancer: A review of epidemiology, pathogenesis, staging workup and treatment modalities. World J Gastrointest Oncol. 2014;6(5):112-120. doi:10.4251/wjgo.v6.i5.112
34.
RezaJARamanVVeksteinA, et al. Implementation of screening guidelines in early esophageal cancer: A Study of the Society of Thoracic Surgeons General Thoracic Surgery Database. Ann Surg. Published online March13, 2023. doi:10.1097/sla.0000000000005837
35.
TramontanoACChenYWatsonTREckelAHurCKongCY. Esophageal cancer treatment costs by phase of care and treatment modality, 2000-2013. Cancer Med. 2019;8(11):5158-5172. doi:10.1002/cam4.2451
36.
LinebackCMMervakCMRevelsSLKempMTReddyRM. Barriers to accessing optimal esophageal cancer care for socioeconomically disadvantaged patients. Ann Thorac Surg. 2017;103(2):416-421. doi:10.1016/j.athoracsur.2016.08.085
37.
AroraNLoMHannaNM, et al. Influence of a patient navigation program on timeliness of care in patients with esophageal cancer. Cancer Med. 2023;12(10):11907–11914. doi:10.1002/cam4.5882
38.
HuangBXuMCPennathurA, et al. Endoscopic resection with adjuvant treatment versus esophagectomy for early-stage esophageal cancer. Surg Endosc. 2022;36(3):1868-1875. doi:10.1007/s00464-021-08466-2
39.
LamMBRaphaelKMehtsunWT, et al. Changes in racial disparities in mortality after cancer surgery in the US, 2007-2016. JAMA Netw Open. 2020;3(12):e2027415. doi:10.1001/jamanetworkopen.2020.27415
40.
DongJGuXEl-SeragHBThriftAP. Underuse of surgery accounts for racial disparities in esophageal cancer survival times: A matched cohort study. Clin Gastroenterol Hepatol. 2019;17(4):657-665.e13. doi:10.1016/j.cgh.2018.07.018
41.
MerrittREAbdel-RasoulMD'SouzaDMKneuertzPJ. Racial disparities in provider recommendation for esophagectomy for esophageal carcinoma. J Surg Oncol. 2021;124(4):521-528. doi:10.1002/jso.26549
42.
SavitchSLGrendaTRScottW, et al. Racial disparities in rates of surgery for esophageal cancer: a study from the National Cancer Database. J Gastrointest Surg. 2021;25(3):581-592. doi:10.1007/s11605-020-04653-z
43.
LevinskyNCWimaKMorrisMC, et al. Outcome of delayed versus timely esophagectomy after chemoradiation for esophageal adenocarcinoma. J Thorac Cardiovasc Surg. 2020;159(6):2555-2566. doi:10.1016/j.jtcvs.2019.09.169
44.
SridharPBhattMQureshiMM, et al. Esophageal cancer presentation, treatment, and outcomes vary with hospital safety-net burden. Ann Thorac Surg. 2019;107(5):1472-1479. doi:10.1016/j.athoracsur.2018.11.065
45.
SchlottmannFGaberCStrasslePDHerbellaFAMMolenaDPattiMG. Disparities in esophageal cancer: less treatment, less surgical resection, and poorer survival in disadvantaged patients. Dis Esophagus. 2020;33(2):doz045. doi:10.1093/dote/doz045
46.
MorenoACZhangNVermaVGiordanoSHLinSH. Treatment disparities affect outcomes for patients with stage I esophageal cancer: a national cancer data base analysis. J Gastrointest Oncol. 2018;10(1):74-84. doi:10.21037/jgo.2018.10.04
47.
MolenaDMungoBStemMPouporeAKChenSYLidorAO. Does Quality of care matter? A study of adherence to National Comprehensive Cancer Network guidelines for patients with locally advanced esophageal cancer. J Gastrointest Surg. 2015;19(10):1739-1747. doi:10.1007/s11605-015-2899-8
48.
JohnsonRLRoterDPoweNRCooperLA. Patient race/ethnicity and quality of patient–physician communication during medical visits. Am J Public Health. 2004;94(12):2084-2090. doi:10.2105/ajph.94.12.2084
49.
JordanTMastnakDMPalamarNKozjekNR. Nutritional therapy for patients with esophageal cancer. Nutr Cancer. 2018;70(1):23-29. doi:10.1080/01635581.2017.1374417
50.
Paniagua CruzAHaugKLZhaoLReddyRM. Association between marital status and racial disparities in esophageal cancer care. J Oncol Pract. 2020;16(6):e498-e506. doi:10.1200/jop.19.00561
51.
BaiuIBackhusL. Esophageal Cancer Surgery. JAMA. 2020;324:1580.
52.
ManigrassoMVertaldiSMarelloA, et al. Robotic esophagectomy. A systematic review with meta-analysis of clinical outcomes. J Pers Med. 2021;11(7):640. doi:10.3390/jpm11070640
53.
AngeramoCABras HarriottCCasasMASchlottmannF. Minimally invasive Ivor Lewis esophagectomy: robot-assisted versus laparoscopic–thoracoscopic technique. Systematic review and meta-analysis. Surgery. 2021;170(6):1692-1701. doi:10.1016/j.surg.2021.07.013
54.
van BoxelGIKingmaBFVoskensFJRuurdaJPvan HillegersbergR. Robotic-assisted minimally invasive esophagectomy: past, present and future. J Thorac Dis. 2020;12(2):54-62. doi:10.21037/jtd.2019.06.75
55.
BiereSSvan Berge HenegouwenMIMaasKW, et al. Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicentre, open-label, randomised controlled trial. Lancet. 2012;379(9829):1887-1892. doi:10.1016/s0140-6736(12)60516-9
56.
HorseyMLLaiDSparksAD, et al. Disparities in utilization of robotic surgery for colon cancer: an evaluation of the U.S. National Cancer Database. J Robot Surg. 2022;16(6):1299-1306. doi:10.1007/s11701-022-01371-3
57.
KimSPBoorjianSAShahND, et al. Disparities in access to hospitals with robotic surgery for patients with prostate cancer undergoing radical prostatectomy. J Urol. 2013;189(2):514-520. doi:10.1016/j.juro.2012.09.033
58.
RehmaniSSLiuBAl-AyoubiAM, et al. Racial disparity in utilization of high-volume hospitals for surgical treatment of esophageal cancer. Ann Thorac Surg. 2018;106(2):346-353. doi:10.1016/j.athoracsur.2018.03.042
59.
TranPNTaylorTHKlempnerSJZellJA. The impact of gender, race, socioeconomic status, and treatment on outcomes in esophageal cancer: A population-based analysis. J Carcinog. 2017;16:3. doi:10.4103/jcar.JCar_4_17
60.
ClarkJMBoffaDJMeguidRABrownLMCookeDT. Regionalization of esophagectomy: where are we now?J Thorac Dis. 2019;11(Suppl 12):S1633-S1642. doi:10.21037/jtd.2019.07.88
61.
HuangZDGuHYZhuJ, et al. The application of enhanced recovery after surgery for upper gastrointestinal surgery: meta-analysis. BMC Surg. 2020;20(1):3. doi:10.1186/s12893-019-0669-3
62.
MarquesICWahlTSChuDI. Enhanced recovery after surgery and surgical disparities. Surg Clin N Am. 2018;98(6):1223-1232. doi:10.1016/j.suc.2018.07.015
63.
WahlTSGossLEMorrisMS, et al. Enhanced Recovery after Surgery (ERAS) eliminates racial disparities in postoperative length of stay after colorectal surgery. Ann Surg. 2018;268(6):1026-1035. doi:10.1097/sla.0000000000002307
64.
SpringerJEDoumourasAGLethbridgeSForbesSEskiciogluC. A provincial assessment of the barriers and utilization of enhanced recovery after colorectal surgery. J Surg Res. 2019;235:521-528. doi:10.1016/j.jss.2018.10.047
65.
PlumPSGebauerFKrämerM, et al. HER2/neu (ERBB2) expression and gene amplification correlates with better survival in esophageal adenocarcinoma. BMC Cancer. 2019;19(1):38. doi:10.1186/s12885-018-5242-4
66.
BangYJVan CutsemEFeyereislovaA, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687-697. doi:10.1016/s0140-6736(10)61121-x
67.
StroesCIvan den EndeTDerksSvan LaarhovenHWM. A systematic review of HER2 blockade for the curative treatment of gastroesophageal adenocarcinoma: successes achieved and opportunities ahead. Cancer Treat Rev. 2021;99:102249. doi:10.1016/j.ctrv.2021.102249
68.
Teixeira FarinhaHDigkliaASchizasDDemartinesNSchäferMMantziariS. Immunotherapy for esophageal cancer: state-of-the Art in 2021. Cancers. 2022Feb;14(3): 554. doi:10.3390/cancers14030554
69.
TurnerBESteinbergJRWeeksBTRodriguezFCullenMR. Race/ethnicity reporting and representation in US clinical trials: a cohort study. Lancet Reg Health Am. 2022;11:100252. doi:10.1016/j.lana.2022.100252
70.
Hasson CharlesRMSosaEPatelMErhunmwunseeL. Health disparities in recruitment and enrollment in Research. Thorac Surg Clin. 2022;32(1):75-82. doi:10.1016/j.thorsurg.2021.09.012
71.
ErhunmwunseeLGulackBCRushingCNiedzwieckiDBerryMFHartwigMG. Socioeconomic status, not race, is associated with reduced survival in esophagectomy patients. Ann Thorac Surg. 2017;104(1):234-244. doi:10.1016/j.athoracsur.2017.01.049
72.
NadeemMFKaiserLR. Disparities in Health Care Delivery Systems. Thorac Surg Clin. 2022;32(1):13-21. doi:10.1016/j.thorsurg.2021.09.005
73.
CeppaDP. Social disparities in the Thoracic Surgery Workforce. Thorac Surg Clin. 2022;32(1):103-109. doi:10.1016/j.thorsurg.2021.09.002
74.
ErkmenCPOrtmeyerKAPelletierGJPreventzaOCookeDT. An approach to diversity and inclusion in cardiothoracic surgery. Ann Thorac Surg. 2021;111(3):747-752. doi:10.1016/j.athoracsur.2020.10.056
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
